cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc25plfx
title: CCDC 2016749: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25plgy
title: CCDC 2016750: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25plhz
title: CCDC 2016751: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25plj0
title: CCDC 2016752: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25plk1
title: CCDC 2016753: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25pll2
title: CCDC 2016754: Experimental Crystal Structure Determination

description: Related Article: Jonathan C. Bristow, Isaac Naftalin, Stacey V. A. Cliff, Songjie Yang, Marina Carravetta, Ivo Heinmaa, Raivo Stern, John D. Wallis|2020|CrystEngComm|22|6783|doi:10.1039/D0CE01137A
DOI: 10.5517/ccdc.csd.cc25qh9q
title: CCDC 2017613: Experimental Crystal Structure Determination

description: Related Article: Chen-Lan Lin, Yan-Fei Chen, Li-Juan Qiu, Binglong Zhu, Xin Wang, Shi-Peng Luo, Wenyan Shi, Ting-Hai Yang, Wu Lei|2020|CrystEngComm|22|6847|doi:10.1039/D0CE01054E
DOI: 10.5517/ccdc.csd.cc25qhbr
title: CCDC 2017614: Experimental Crystal Structure Determination

description: Related Article: Chen-Lan Lin, Yan-Fei Chen, Li-Juan Qiu, Binglong Zhu, Xin Wang, Shi-Peng Luo, Wenyan Shi, Ting-Hai Yang, Wu Lei|2020|CrystEngComm|22|6847|doi:10.1039/D0CE01054E
DOI: 10.5517/ccdc.csd.cc25qhcs
title: CCDC 2017615: Experimental Crystal Structure Determination

description: Related Article: Chen-Lan Lin, Yan-Fei Chen, Li-Juan Qiu, Binglong Zhu, Xin Wang, Shi-Peng Luo, Wenyan Shi, Ting-Hai Yang, Wu Lei|2020|CrystEngComm|22|6847|doi:10.1039/D0CE01054E
DOI: 10.5517/ccdc.csd.cc25q5ps
title: CCDC 2017315: Experimental Crystal Structure Determination

description: Related Article: Mainak Karmakar, Antonio Frontera, Shouvik Chattopadhyay|2020|CrystEngComm|22|6876|doi:10.1039/D0CE01105C
DOI: 10.5517/ccdc.csd.cc25q5qt
title: CCDC 2017316: Experimental Crystal Structure Determination

description: Related Article: Mainak Karmakar, Antonio Frontera, Shouvik Chattopadhyay|2020|CrystEngComm|22|6876|doi:10.1039/D0CE01105C
DOI: 10.5517/ccdc.csd.cc25q5rv
title: CCDC 2017317: Experimental Crystal Structure Determination

description: Related Article: Mainak Karmakar, Antonio Frontera, Shouvik Chattopadhyay|2020|CrystEngComm|22|6876|doi:10.1039/D0CE01105C
DOI: 10.5517/ccdc.csd.cc25qdbn
title: CCDC 2017521: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qdcp
title: CCDC 2017522: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qddq
title: CCDC 2017523: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qdfr
title: CCDC 2017524: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qdgs
title: CCDC 2017525: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qdht
title: CCDC 2017526: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25qdjv
title: CCDC 2017527: Experimental Crystal Structure Determination

description: Related Article: Yuji Sumimoto, Kodai Iijima, Dongho Yoo, Tadashi Kawamoto, Yann Le Gal, Dominique Lorcy, Takehiko Mori|2020|CrystEngComm|22|6920|doi:10.1039/D0CE01133A
DOI: 10.5517/ccdc.csd.cc25vtwr
title: CCDC 2021785: Experimental Crystal Structure Determination

description: Related Article: Houting Liu, Rongyun Li, Jing Lu, Zhiliang Liu, Suna Wang, Haiquan Tian|2020|CrystEngComm|22|6935|doi:10.1039/D0CE01197E
DOI: 10.5517/ccdc.csd.cc25vtzv
title: CCDC 2021788: Experimental Crystal Structure Determination

description: Related Article: Houting Liu, Rongyun Li, Jing Lu, Zhiliang Liu, Suna Wang, Haiquan Tian|2020|CrystEngComm|22|6935|doi:10.1039/D0CE01197E
DOI: 10.5517/ccdc.csd.cc25vtyt
title: CCDC 2021787: Experimental Crystal Structure Determination

description: Related Article: Houting Liu, Rongyun Li, Jing Lu, Zhiliang Liu, Suna Wang, Haiquan Tian|2020|CrystEngComm|22|6935|doi:10.1039/D0CE01197E
DOI: 10.5517/ccdc.csd.cc25vtxs
title: CCDC 2021786: Experimental Crystal Structure Determination

description: Related Article: Houting Liu, Rongyun Li, Jing Lu, Zhiliang Liu, Suna Wang, Haiquan Tian|2020|CrystEngComm|22|6935|doi:10.1039/D0CE01197E
DOI: 10.6084/m9.figshare.13143380
title: SI Fig10

description: SI Fig10
DOI: 10.6084/m9.figshare.13143380.v1
title: SI Fig10

description: SI Fig10
DOI: 10.6084/m9.figshare.13143377
title: SI Fig6

description: SI Fig6
DOI: 10.6084/m9.figshare.13143377.v1
title: SI Fig6

description: SI Fig6
DOI: 10.6084/m9.figshare.13143368.v1
title: SI Fig5

description: SI Fig5
DOI: 10.6084/m9.figshare.13143368
title: SI Fig5

description: SI Fig5
DOI: 10.6084/m9.figshare.13143347
title: Fig3

description: Fig3
DOI: 10.6084/m9.figshare.13143347.v1
title: Fig3

description: Fig3
DOI: 10.6084/m9.figshare.13130138
title: Fig2

description: Fig2
DOI: 10.5255/ukda-sn-853810
title: Social assistance in low and middle income countries 2000-2015

description: The social assistance explorer contains a harmonised panel dataset of social assistance indicators spanning 2000-2015. It has been developed to support comparative research on emerging welfare institutions. Comparative analysis of social protection institutions in low and middle income countries is scarce. Yet social assistance accounts for most of the recent expansion of welfare institutions. The project collected data on programme design and objectives, institutionalisation, reach, and financial resources. Key indicators can be aggregated at country and region levels.
DOI: 10.21227/g3m8-b323
title: The ''metamery'' of carbon nanostructures: from single flakes to stakes and rouleaux phenomena

description: See our next articles.
DOI: 10.5281/zenodo.4134737
title: Human Kalirin/RAC1 GEF/GTPase Complex

description: We have cloned, expressed, purified and crystallised the first DH GEF domain of Kalirin (gene: KALRN) in complex with RAC1 (gene: RAC1) as part of a programme to explore a new way of targeting GTPases. Fragment screening and X-ray crystallography has identified binders within the orthosteric binding site. A nucleotide exchange assay has been developed and GEF activity established.
description: This document represents version 2 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep
DOI: 10.5281/zenodo.3266933
title: Human Kalirin/RAC1 GEF/GTPase Complex

description: We have cloned, expressed, purified and crystallised the first DH GEF domain of Kalirin (gene: KALRN) in complex with RAC1 (gene: RAC1) as part of a programme to explore a new way of targeting GTPases. Fragment screening and X-ray crystallography has identified binders within the orthosteric binding site. A nucleotide exchange assay has been developed and GEF activity established.
description: This document represents version 2 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep
DOI: 10.6084/m9.figshare.13143419
title: Fig1

description: Fig1
DOI: 10.5281/zenodo.4134552
title: Human With No Lysine Kinase 3 (WNK3); A Target Enabling Package

description: Kinases WNK1-4 regulate cation-chloride cotransporters via phosphorylation of SPAK and OSR1 and thereby control salt homeostasis, cell volume and blood pressure. Gain of function mutations in WNK kinases are found in Gordon’s hypertension syndrome suggesting the WNK pathway as a therapeutic target. WNK3 inhibition in particular has also been shown to reduce cerebral injury after Ischemic stroke. Here we present assays and crystal structures that define (i) the molecular basis for disease mutations; (ii) the multiple functional domains of WNK kinases and their protein interactions; (iii) the binding of small molecule kinase inhibitors and a potential allosteric pocket.
description: This document represents version 7 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.1219718
title: Human With No Lysine Kinase 3 (WNK3); A Target Enabling Package

description: Kinases WNK1-4 regulate cation-chloride cotransporters via phosphorylation of SPAK and OSR1 and thereby control salt homeostasis, cell volume and blood pressure. Gain of function mutations in WNK kinases are found in Gordon’s hypertension syndrome suggesting the WNK pathway as a therapeutic target. WNK3 inhibition in particular has also been shown to reduce cerebral injury after Ischemic stroke. Here we present assays and crystal structures that define (i) the molecular basis for disease mutations; (ii) the multiple functional domains of WNK kinases and their protein interactions; (iii) the binding of small molecule kinase inhibitors and a potential allosteric pocket.
description: This document represents version 7 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.4134531
title: Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2); A Target Enabling Package

description: RIPK2 inflammatory signalling downstream from the bacteria-sensing receptors NOD1 and NOD2 is associated with auto-immune and inflammatory conditions. RIPK2 inhibition has shown promise in disease models of inflammatory bowel disease and multiple sclerosis. In this TEP, we reveal a lack of correlation between inhibitor efficacy in cells and their potency using in vitro kinase assays. We show that RIPK2 kinase activity is in fact dispensable for NOD2 inflammatory signalling and that RIPK2 inhibitors function instead by antagonizing XIAP-binding and ubiquitination of RIPK2. We characterise the molecular basis for this effect. We also solved the first crystal structure of the RIPK2 kinase domain and applied a range of biochemical and cellular assays to profile type I and type II RIPK2 kinase inhibitors. Overall, our study illustrates how to target the ATP-binding pocket in RIPK2 to interfere with the RIPK2-XIAP interaction for modulation of NOD signalling.
description: This document represents version 3 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.1344501
title: Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2); A Target Enabling Package

description: RIPK2 inflammatory signalling downstream from the bacteria-sensing receptors NOD1 and NOD2 is associated with auto-immune and inflammatory conditions. RIPK2 inhibition has shown promise in disease models of inflammatory bowel disease and multiple sclerosis. In this TEP, we reveal a lack of correlation between inhibitor efficacy in cells and their potency using in vitro kinase assays. We show that RIPK2 kinase activity is in fact dispensable for NOD2 inflammatory signalling and that RIPK2 inhibitors function instead by antagonizing XIAP-binding and ubiquitination of RIPK2. We characterise the molecular basis for this effect. We also solved the first crystal structure of the RIPK2 kinase domain and applied a range of biochemical and cellular assays to profile type I and type II RIPK2 kinase inhibitors. Overall, our study illustrates how to target the ATP-binding pocket in RIPK2 to interfere with the RIPK2-XIAP interaction for modulation of NOD signalling.
description: This document represents version 3 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.21227/0xzt-9q82
title: The ''metamery'' of carbon nanostructures: from single flakes to stakes and rouleaux phenomena

description: See our next articles.
DOI: 10.5281/zenodo.1407682
title: Electron diffraction datasets from IRELOH and EPICZA

description: Electron diffraction datasets of IRELOH (CDCC IREOLH01) and EPICZA (CDCC BISGAO), collected on a FEI Polara operated at 200 kV with a 512x512 pixels Timepix hybrid pixel detector (55x55 micron pixel size).
DOI: 10.5281/zenodo.1407681
title: Electron diffraction datasets from IRELOH and EPICZA

description: Electron diffraction datasets of IRELOH (CDCC IREOLH01) and EPICZA (CDCC BISGAO), collected on a FEI Polara operated at 200 kV with a 512x512 pixels Timepix hybrid pixel detector (55x55 micron pixel size).
DOI: 10.5281/zenodo.4134328
title: Human Cyclin-dependent kinase 12 (CDK12), kinase domain; A Target Enabling Package

description: Cyclin-dependent kinase 12 (CDK12) phosphorylates RNA Pol II C-terminal domain (CTD) to promote transcriptional elongation of large DNA damage response genes. CDK12 is frequently mutated or amplified in cancer and its loss sensitises cells to DNA damage. Here we present 3 crystal structures of the human CDK12/CycK complex including apo, AMP-PNP and covalent inhibitor complexes. Kinase assays compare domain truncations and report the Km values for substrate. THZ531 is presented as a potent and selective inhibitor of CDK12 with nanomolar activity in leukemic cell lines.
description: This document represents version 8 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.21227/vs16-k269
title: The ''metamery'' of carbon nanostructures: from single flakes to stakes and rouleaux phenomena

description: See our next articles.
DOI: 10.5281/zenodo.4134457
title: Human Kelch-like Protein 20 (KLHL20); A Target Enabling Package

description: The BTB-Kelch protein KLHL20 is a hypoxia-induced CUL3-dependent E3 ligase linked to autophagy, Alzheimer’s disease and cancer. KLHL20 acts to terminate autophagy by promoting the ubiquitination and degradation of ULK1. KLHL20 is also reported as a top 20 biomarker for Alzheimer’s disease progression. Inhibition of KLHL20 may be neuroprotective by extending autophagy for the clearance of neurotoxic proteins aggregates. KLHL20 also promotes cancer through the ubiquitination and degradation of tumour suppressors including PML and DAPK1. We have solved the 1.1 Å structure of the Kelch domain of KLHL20 in complex with a DAPK1 peptide. We have used biophysical and cellular studies to validate this peptide site as a degron site for DAPK1 degradation. Using this peptide, we have also established alpha screen and HTRF assays to identify potent small molecule covalent inhibitors that compete with DAPK1 for binding to the Kelch domain of KLHL20.
description: This document represents version 2 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep
DOI: 10.5281/zenodo.3245315
title: Human Kelch-like Protein 20 (KLHL20); A Target Enabling Package

description: The BTB-Kelch protein KLHL20 is a hypoxia-induced CUL3-dependent E3 ligase linked to autophagy, Alzheimer’s disease and cancer. KLHL20 acts to terminate autophagy by promoting the ubiquitination and degradation of ULK1. KLHL20 is also reported as a top 20 biomarker for Alzheimer’s disease progression. Inhibition of KLHL20 may be neuroprotective by extending autophagy for the clearance of neurotoxic proteins aggregates. KLHL20 also promotes cancer through the ubiquitination and degradation of tumour suppressors including PML and DAPK1. We have solved the 1.1 Å structure of the Kelch domain of KLHL20 in complex with a DAPK1 peptide. We have used biophysical and cellular studies to validate this peptide site as a degron site for DAPK1 degradation. Using this peptide, we have also established alpha screen and HTRF assays to identify potent small molecule covalent inhibitors that compete with DAPK1 for binding to the Kelch domain of KLHL20.
description: This document represents version 2 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep
DOI: 10.5281/zenodo.4134502
title: Human LIM domain kinase 1 (LIMK1), kinase domain; A Target Enabling Package

description: Loss of the translational repressor FMRP in fragile X syndrome causes upregulation of the type II BMP receptor BMPR2 and its non-canonical signalling via the kinase LIMK1. LIMK1 performs inhibitory phosphorylation on cofilin proteins blocking their actin-severing activity. Excessive BMPR2-LIMK1 activation was associated with dendritic spine and behavioural defects in animal models that could be rescued by BMPR2 knockdown or LIMK1 inhibition. Here we present a target enabling package for the therapeutic target LIMK1. We include crystal structures of BMPR2, LIMK1, LIMK2 and the LIMK1-cofilin complex, as well as multiple assays for small molecule inhibitor screening. Finally, we identify a series of allosteric LIMK1 inhibitors with promising potency and selectivity that may potentially allow the development of a safe drug for this chronic indication.
description: This document represents version 7 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.1219706
title: Human LIM domain kinase 1 (LIMK1), kinase domain; A Target Enabling Package

description: Loss of the translational repressor FMRP in fragile X syndrome causes upregulation of the type II BMP receptor BMPR2 and its non-canonical signalling via the kinase LIMK1. LIMK1 performs inhibitory phosphorylation on cofilin proteins blocking their actin-severing activity. Excessive BMPR2-LIMK1 activation was associated with dendritic spine and behavioural defects in animal models that could be rescued by BMPR2 knockdown or LIMK1 inhibition. Here we present a target enabling package for the therapeutic target LIMK1. We include crystal structures of BMPR2, LIMK1, LIMK2 and the LIMK1-cofilin complex, as well as multiple assays for small molecule inhibitor screening. Finally, we identify a series of allosteric LIMK1 inhibitors with promising potency and selectivity that may potentially allow the development of a safe drug for this chronic indication.
description: This document represents version 7 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.4134590
title: Human Peroxisomal Coenzyme A Diphosphatase (NUDT7); A Target Enabling Package

description: In an effort to characterise the human NUDIX family SGC Oxford has expressed recombinant human NUDT7 as part of the SGC chemical probe programme and solved the first crystal structure of this enzyme. This enabled a crystallographic fragment screen which in conjunction with a separate covalent fragment approach yielded a first-in-class small molecule inhibitor of NUDT7 with activity in the single-digit micromolar range in a catalytic assay. This compound paves the way for chemical probe development and further functional exploration of NUDT7 in physiological and disease contexts.
description: This document represents version 3 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.1343363
title: Human Peroxisomal Coenzyme A Diphosphatase (NUDT7); A Target Enabling Package

description: In an effort to characterise the human NUDIX family SGC Oxford has expressed recombinant human NUDT7 as part of the SGC chemical probe programme and solved the first crystal structure of this enzyme. This enabled a crystallographic fragment screen which in conjunction with a separate covalent fragment approach yielded a first-in-class small molecule inhibitor of NUDT7 with activity in the single-digit micromolar range in a catalytic assay. This compound paves the way for chemical probe development and further functional exploration of NUDT7 in physiological and disease contexts.
description: This document represents version 3 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.4134700
title: Human Pleckstrin Homology domain Interacting Protein (PHIP); A Target Enabling Package

description: SGC Oxford has expressed, purified and crystallized the second bromodomain of PHIP as part of the probe programme. Fragment screening and X-ray crystallography identified binders, some of which optimised to uM affinity. However, molecules with probe properties were not obtained. Consequently it has been decided to put the information generated into the public domain.
description: This document represents version 6 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.
DOI: 10.5281/zenodo.1219712
title: Human Pleckstrin Homology domain Interacting Protein (PHIP); A Target Enabling Package

description: SGC Oxford has expressed, purified and crystallized the second bromodomain of PHIP as part of the probe programme. Fragment screening and X-ray crystallography identified binders, some of which optimised to uM affinity. However, molecules with probe properties were not obtained. Consequently it has been decided to put the information generated into the public domain.
description: This document represents version 6 of the TEP datasheet and includes all updates on the project as of October 2020. For more information about TEPs and the TEP Programme, please visit https://thesgc.org/tep.